Sihuan Pharmaceutical Holding Group Co., Ltd. (“Sihuan Pharmaceutical” or the “Company”, together with its subsidiaries is the “Group”) (stock code: 00460.HK) was founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010. It is an international medical, aesthetic and biopharmaceutical enterprise with an independent and leading independent production, research and development (“R&D”) technology platform led by innovation and a mature and excellent sales system. Sihuan Pharmaceutical focuses on high-growth treatment fields such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular, modern traditional Chinese medicine, and industrial marijuana, and has always adhered to the overall strategic goal of “adhering to the full speed promotion of Sihuan Medical Aesthetics and Biopharmaceuticals two-wheel drive strategy” to build a leading medical, aesthetic and biopharmaceutical enterprise in China.